Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04977674

Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine — GO-MARK  

Depressive Disorder, Treatment-Resistant Clinical Trial

Official title:
Investigating Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine

Clinical Trial Summary

The overarching aim of this research is to determine the acute effects of ketamine on brain glutamate, functional connectivity and cerebral blood flow in treatment-resistant depression, explore whether the effects are attenuated by the opioid receptor antagonist naltrexone and relate these findings to antidepressant response.

Clinical Trial Description

The study is a randomised, double-blind, crossover design with two treatment conditions: oral placebo or oral naltrexone preceding ketamine infusion during neuroimaging in subjects with treatment-resistant depression. Each subject will participate in two imaging sessions on two separate days. Each subject will receive a dose of ketamine (IV infusion, 0.5 mg/kg over 40 minutes) during each scan. Subjects will receive either oral placebo or naltrexone 50 mg, 45 minutes before the initiation of each of the ketamine infusions. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04977674
Study type Interventional
Source King's College London
Contact
Status Completed
Phase Early Phase 1
Start date September 27, 2021
Completion date February 20, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03851380 - Improving Brain Stimulation Through Imaging
Completed NCT03207282 - Treatment Resistant Depression in America Latina
Completed NCT02452892 - Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD) N/A
Completed NCT02691520 - Epidemiology of Treatment Resistant Depression in Taiwan Phase 4
Active, not recruiting NCT04159012 - NESBID: Neuro-Stimulation of the Brain in Depression N/A
Recruiting NCT05870501 - Synaptic Imaging and Network Activity in Treatment Resistant Depression N/A
Completed NCT04239651 - rTMS With and Without iCBT For the Treatment of Resistant Depression (TRD) N/A
Completed NCT02493868 - A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression Phase 3
Completed NCT04599855 - A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression Phase 4
Completed NCT03283670 - Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies Phase 2
Recruiting NCT03004521 - Lithium Versus Quetiapine in Treatment Resistant Depression Phase 4
Recruiting NCT04783103 - Neuromodulation in the Elderly Depressed: a Brain Imaging Pilot Study N/A
Completed NCT03434041 - A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression Phase 3
Terminated NCT03887624 - Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression. Early Phase 1
Completed NCT02577250 - Ketamine Infusions for PTSD and Treatment-Resistant Depression Phase 1
Recruiting NCT02610712 - Clinical Trial of the Use of Ketamine in Treatment Resistant Depression Phase 4
Completed NCT03051256 - Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD Phase 2
Enrolling by invitation NCT05581797 - Psilocybin-assisted Interpersonal Therapy for Depression N/A
Completed NCT02782104 - A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression Phase 3
Completed NCT04216888 - Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine Phase 2/Phase 3